Results 111 to 120 of about 50,263 (243)
Journal of Intelligent Medicine, EarlyView.Abstract In recent years, the clinical treatment and symptom management of neurological disorders have faced significant challenges due to the high complexity of the nervous system's structure and function. Against this backdrop, physical stimulation techniques have emerged as a vital complementary approach to traditional pharmacological treatments and
Wanying Li, Liqun Chen
wiley +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT Nitrooxidative stress, driven by excess reactive nitrogen species like peroxynitrite, contributes to the pathogenesis of many chronic diseases. Among its molecular footprints, 3‐nitrotyrosine (3NT) has emerged as a biologically relevant marker of protein nitration.
Brîndușa Alina Petre
wiley +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu +5 more
wiley +1 more source
Recent Advances in Top‐Down Proteomics for Single‐Cell Research
Mass Spectrometry Reviews, EarlyView.ABSTRACT Individual cells have distinctive molecular characteristics, including biologically relevant proteoforms. Although single‐cell (SC) molecular omics offer unprecedented insights into cellular heterogeneity and function, the characterization of proteoforms in SCs remains an uncharted territory.
Jake A. Melby, Pei Su, Fabio P. Gomes
wiley +1 more source
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil +5 more
wiley +1 more source
Quantitative Assessment of Visible Nigrosome‐1 in Patients with Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background The nigrosome‐1 (N1) sign on susceptibility‐weighted imaging (SWI) typically disappears in Parkinson's disease (PD), though some patients can show uni−/bilaterally preserved N1. Objective Investigating whether visible nigrosomes in PD patients differ from those of healthy subjects (HC). Methods Forty‐eight PD and 35 HC underwent 3 T‐
Maria Eugenia Caligiuri +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham +8 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse +224 more
wiley +1 more source